Figure 1: ECL-based assay analysis and cytotoxicity of first discovery cohort. (A) CSF from MS patients with oligoclonal bands positive (OCB+) revealed higher reactivity against myelin as compared with OND with (OCB+) and without OCB (OCB-). When reactivity against myelin and non-myelin membrane was compared, CSF from MS patients showed higher reactivity to myelin. OND OCB+ and OND OCB- did not show any difference in reactivity against myelin as compared with the non-myelin fraction (*p < 0.05, **p < 0.01, ***p < 0.001; two-way ANOVA). (B) CSF and complement components were added to cultures of fully differentiated oligodendrocytes and cell viability was measured after 24 hr using the MTT assay. A subgroup of MS patients with the highest reactivity towards myelin (ECL score against myelin higher than mean) was selected and the cell viability was assessed as compared with the complement control (*p < 0.05, **p < 0.01; one-way ANOVA). (C) The viability of cells treated with CSF from MS patients showed a negative correlation with the ECL score signal intensity against the myelin fraction (Pearson correlation test).